Nicholas C. Turner
#129,154
Most Influential Person Now
Nicholas C. Turner's AcademicInfluence.com Rankings
Nicholas C. Turnerbiology Degrees
Biology
#8395
World Rank
#11463
Historical Rank
Molecular Biology
#1060
World Rank
#1084
Historical Rank
Biochemistry
#1212
World Rank
#1331
Historical Rank
Download Badge
Biology
Nicholas C. Turner's Degrees
- PhD Molecular Biology Stanford University
- Bachelors Biochemistry University of California, Berkeley
Why Is Nicholas C. Turner Influential?
(Suggest an Edit or Addition)Nicholas C. Turner's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Fibroblast growth factor signalling: from development to cancer (2010) (2212)
- Hallmarks of 'BRCAness' in sporadic cancers (2004) (1593)
- The history and future of targeting cyclin-dependent kinases in cancer therapy (2015) (1223)
- Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. (2006) (1221)
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. (2016) (1176)
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer (2015) (844)
- Treating cancer with selective CDK4/6 inhibitors (2016) (725)
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018) (674)
- Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. (2015) (634)
- FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. (2010) (631)
- BRCA1 dysfunction in sporadic basal-like breast cancer (2007) (609)
- Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. (2015) (550)
- Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. (2016) (503)
- Basal-like breast cancer and the BRCA1 phenotype (2006) (486)
- Advances and challenges in targeting FGFR signalling in cancer (2017) (458)
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. (2016) (430)
- Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer (2015) (426)
- Genetic heterogeneity and cancer drug resistance. (2012) (398)
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets (2009) (385)
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. (2018) (367)
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. (2018) (355)
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor (2008) (318)
- The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. (2018) (305)
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer (2010) (288)
- FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas (2006) (280)
- FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis (2007) (273)
- Utilizing RNA interference to enhance cancer drug discovery (2007) (258)
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer (2013) (255)
- Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer (2018) (255)
- Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. (2012) (249)
- Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia (2015) (232)
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. (2021) (215)
- High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. (2016) (205)
- Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. (2008) (205)
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer (2019) (188)
- A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. (2008) (181)
- Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours (2010) (179)
- Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer (2017) (176)
- Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. (2019) (176)
- Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). (2016) (176)
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
- Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. (2005) (172)
- Targeting the DNA repair defect of BRCA tumours. (2005) (168)
- FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo (2011) (164)
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. (2019) (162)
- Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR (2013) (157)
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer. (2016) (156)
- Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer (2017) (156)
- Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future (2020) (153)
- Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours (2015) (151)
- Functional viability profiles of breast cancer. (2011) (151)
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. (2021) (150)
- Advances in the treatment of advanced oestrogen-receptor-positive breast cancer (2017) (148)
- Tackling the Diversity of Triple-Negative Breast Cancer (2013) (143)
- Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial (2020) (129)
- Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets (2009) (125)
- Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer (2020) (119)
- Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. (2013) (108)
- Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer (2018) (102)
- Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. (2017) (97)
- Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance (2017) (94)
- A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) (2018) (91)
- Targeting the PI3-kinase pathway in triple negative breast cancer. (2019) (91)
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. (2021) (84)
- Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) (2019) (83)
- DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. (2013) (78)
- Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial (2019) (75)
- Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma (2017) (74)
- Tumour selective targeting of cell cycle kinases for cancer treatment. (2013) (68)
- Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases (2018) (66)
- Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? (2012) (64)
- An update on the medical management of breast cancer (2014) (60)
- Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). (2017) (58)
- AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. (2018) (57)
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. (2022) (55)
- Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach (2015) (55)
- Hepatitis C and B-cell lymphoma. (2003) (54)
- Modeling Therapy Resistance in BRCA1/2-Mutant Cancers (2017) (54)
- TP53 mutation‐correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53‐mutated breast cancers (2014) (54)
- Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways (2015) (50)
- Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. (2018) (50)
- Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer (2018) (48)
- Targeting the PI3-kinase pathway in triple-negative breast cancer. (2019) (47)
- Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. (2019) (46)
- Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. (2018) (46)
- Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. (2020) (46)
- Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance (2019) (44)
- ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials (2020) (43)
- Plasma ESR 1 Mutations and the Treatment of Estrogen Receptor – Positive Advanced Breast Cancer (2016) (43)
- Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYL (2020) (42)
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). (2019) (41)
- Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer (2012) (40)
- Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. (2015) (40)
- LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer (2021) (39)
- Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors (2019) (38)
- BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population (2019) (36)
- Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer (2020) (36)
- Genomic profile of advanced breast cancer in circulating tumour DNA (2021) (36)
- Management of breast cancer—Part I (2008) (34)
- Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment (2021) (34)
- Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. (2021) (33)
- Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) (2020) (32)
- A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. (2011) (32)
- Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. (2020) (32)
- Biomarkers of PARP inhibitor sensitivity (2011) (31)
- Determination of HER2 Amplification Status on Tumour DNA by Digital PCR (2013) (30)
- Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer (2016) (29)
- Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study (2019) (29)
- An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer (2013) (29)
- Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies (2014) (28)
- Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers. (2020) (25)
- Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition (2014) (25)
- CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer. (2016) (25)
- Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA). (2016) (24)
- The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer (2018) (24)
- Management of breast cancer—Part II (2008) (23)
- Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk. (2019) (23)
- A Therapeutic Target for Smoking-Associated Lung Cancer (2010) (20)
- Abstract CT039: Cyclin E1 (CCNE1)expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial (2018) (20)
- ESR1 mutations in metastatic lobular breast cancer patients (2019) (20)
- Identification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibition. (2015) (19)
- Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience (2019) (19)
- Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience. (2017) (19)
- A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. (2020) (18)
- Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results. (2016) (17)
- Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC). (2021) (16)
- Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study (2022) (16)
- BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. (2019) (16)
- Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts (2020) (16)
- Signatures of DNA‐Repair Deficiencies in Breast Cancer (2017) (16)
- Abstract P4-22-06: Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3 (2017) (15)
- Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study (2021) (15)
- Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial (2021) (15)
- Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up (2021) (15)
- IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2–) breast cancer (BC). (2018) (15)
- A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, in FGFR1-amplified and nonamplified metastatic breast cancer (BC). (2011) (14)
- Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant. (2018) (14)
- Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. (2018) (13)
- Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials (2020) (13)
- Science in Focus: Circulating Tumour DNA as a Liquid Biopsy. (2016) (13)
- Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results. (2019) (13)
- Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC) (2020) (13)
- Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience. (2020) (13)
- Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer. (2017) (12)
- Abstract GS3-06: Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010) (2020) (12)
- Targeting receptor tyrosine kinases in HER2-negative breast cancer (2013) (12)
- Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3 (2021) (11)
- Tracking tumor-specific mutations in circulating-free DNA to predict early relapse after treatment of primary breast cancer. (2014) (11)
- Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma. (2017) (11)
- Targeting PIK3CA-mutant advanced breast cancer in the clinical setting. (2017) (10)
- Palbociclib exposure-response analyses in second-line treatment of hormone-receptor positive advanced breast cancer (ABC). (2017) (10)
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update (2022) (10)
- Molecular Testing in Breast Cancer. (2019) (10)
- Assessing HER2 Amplification in Plasma cfDNA. (2018) (10)
- Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3 (2021) (10)
- Abstract P4-22-03: Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2– advanced breast cancer: a pooled analysis from randomized phase 2 and 3 studies (2017) (10)
- PIK3CA mutation enrichment and quantitation from blood and tissue (2020) (10)
- Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations (2019) (10)
- 86OPI3 kinase/mTOR inhibition increases sensitivity of ER positive breast cancers to CDK4/6 inhibition by blocking cell cycle re-entry driven by cyclinD1 and inducing apoptosis (2015) (9)
- Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer. (2010) (9)
- 350TiP A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291) (2020) (9)
- Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3. (2016) (9)
- Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3. (2018) (9)
- A phase III randomized trial of niraparib versus physician’s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13. (2014) (9)
- Tumor and Stem Cell Biology Cancer Research FGFR 1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer (2010) (9)
- Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial. (2019) (8)
- Abstract OT1-03-05: A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously- treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study) (2016) (8)
- Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients withPIK3CA-mutant solid tumors (2020) (8)
- FGFR: Proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours. (2013) (8)
- Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) forPIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 C (2021) (8)
- Predictive Biomarkers and Personalized Medicine Targeting FGFR with Dovitinib ( TKI 258 ) : Preclinical and Clinical Data in Breast Cancer (2013) (7)
- High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (2021) (7)
- Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer. (2022) (7)
- Abstract OT1-06-03: The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010) (2018) (7)
- Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO) (2016) (7)
- Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients withPIK3CA-mutant HR+/HER2- breast cancer (2020) (6)
- Correction: Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. (2016) (6)
- Abstract OT1-03-13: A phase II, double blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer (TNBC)(NCT02423603) (2016) (6)
- Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials. (2018) (6)
- Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer. (2022) (5)
- Abstract P1-14-03: ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial (2018) (5)
- Abstract GS3-06: Primary results of the cTRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer (2022) (5)
- Abstract PD2-04: Baseline circulatingESR1mutation analysis in the randomised phase III EFECT study of fulvestrant versus exemestane in advanced hormone receptor positive breast cancer (2019) (5)
- PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer. (2019) (5)
- A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO). (2015) (5)
- Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses (2022) (4)
- Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy (2013) (4)
- 1O Detection of homologous recombination repair deficiency (HRD) in treatment-naive early triple-negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests (2021) (4)
- Challenges and opportunities in the targeting of fi broblast growth factor receptors in breast cancer (4)
- FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer. (2014) (4)
- Abstract CT109: A phase I/Ib study evaluating GDC-0077 plus fulvestrant in patients withPIK3CA-mutant, hormone receptor-positive/HER2-negative breast cancer (2020) (4)
- Abstract OT1-03-03: FINESSE - An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplIfied oestrogeN rEceptor poSitive metaStatic breast cancEr (2016) (4)
- Abstract GS3-07: The genomic landscape of breast cancer based on ctDNA analysis: Data from the plasmaMATCH trial (2020) (4)
- ESR1 F404 mutations and acquired resistance to fulvestrant in the plasmaMATCH study. (2022) (4)
- Type-1 histiocytosis response to 90Y-lanreotide. (2004) (4)
- Abstract PD2-07: Alpelisib + letrozole in patients withPIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study result (2021) (4)
- 355TiP Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC) (2020) (4)
- Abstract GS3-04: GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial (2023) (4)
- 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study (2021) (3)
- Prognostic and predictive value of ESR1 mutations in postmenopausal metastatic breast cancer (MBC) patients (pts) resistant to aromatase inhibitors (AI), treated with palbociclib (PAL) in combination with endocrine therapy (ET) or capecitabine (CAP) in the PEARL study. (2020) (3)
- Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? (2012) (3)
- Clinical Benefit of Circulating Tumor DNA Analysis in Follow-up of Patients With Early-Stage Breast Cancer-Reply. (2019) (3)
- Understanding divergent trial results of adjuvant CDK4/6 inhibitors for early stage breast cancer. (2021) (3)
- Impact of timing of adjuvant chemotherapy for early breast cancer: the Royal Marsden Hospital experience (2021) (3)
- Integrative Molecular Profiling of Triple Negative Breast Cancers Identifies Potential Therapeutic Targets Including Amplifications of FGFR2. (2009) (3)
- Abstract CT331: “BEECH”, a phase I/II study of the AKT inhibitor AZD5363 combined with paclitaxel in patients with advanced or metastatic breast cancer: results from the dose-finding study, including quantitative assessment of circulating tumor DNA as a s (2015) (3)
- Predicting sensitivity to palbociclib with early circulating tumor DNA dynamics in the PALOMA-3 trial. (2017) (3)
- Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3. (2017) (3)
- 145OPhase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort clinical and translational results (2015) (2)
- Abstract P4-22-07: Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+ HER2– advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies (2017) (2)
- The spatio-temporal evolution of lymph node spread in early breast cancer (2018) (2)
- 43PDevelopment and validation of multiplex digital PCR assays on circulating tumor DNA in advanced breast cancer: Implementation for clinical routine use (2015) (2)
- Endocrine-based therapy versus chemotherapy in advanced breast cancer. (2019) (2)
- Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital (2022) (2)
- Molecular determinants of sensitivity and resistance to FGFR inhibition in FGFR2-amplified gastric cancer (2016) (2)
- Association of drug-related polymorphisms with palbociclib-related neutropenia: Pharmacogenetic analysis of PALOMA-2/-3 (P2/3). (2019) (2)
- Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (2016) (2)
- Abstract 536: Molecular residual disease detection in early stage breast cancer with a personalized sequencing approach (2021) (2)
- Abstract PD1-11: Mature survival update of the double-blind placebo-controlled randomised phase II PAKT trial of first-line capivasertib plus paclitaxel for metastatic triple-negative breast cancer (2021) (2)
- PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination. (2019) (2)
- 44PUnravelling mechanisms of resistance to CDK4/6 inhibitors using triple negative breast cancer (TNBC) (2017) (2)
- A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers. (2017) (2)
- Abstract OT1-1-14: A phase 2, 2-stage, 2-cohort study of the oral PARP inhibitor BMN 673 in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO study) (2015) (2)
- Abstract P1-19-04: Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010) (2020) (2)
- Heterogeneous HER2 Amplification-a New Clinical Category of HER2-Positive Breast Cancer? (2021) (2)
- Abstract 926: ESR1 mutations evolve during the treatment of metastatic breast cancer, and detection in ctDNA predicts sensitivity to subsequent hormone therapy (2015) (2)
- Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. (2018) (2)
- Palbociclib and Fulvestrant in Breast Cancer. Reply. (2019) (2)
- Abstract S6-02: Occurrence of natural ESR1 mutations during acquisition of endocrine resistance in breast cancers and widely used ER+ cell lines (2016) (2)
- 163 Functional Screens to Identify Mechanisms of Resistance to FGFR Inhibitors in FGFR Amplified and Mutated Cell Lines (2012) (2)
- Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations (2019) (1)
- Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve. (2021) (1)
- persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC). (2021) (1)
- Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer (2018) (1)
- Vinorelbine After Prior Treatment With Eribulin for Advanced Breast Cancer: A Single-Centre Experience Suggesting Cross-Resistance. (2022) (1)
- Abstract P4-13-01: PALOMA3: Phase 3 trial of fulvestrant with or without palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy—confirmed efficacy and safety (2016) (1)
- Abstract P5-17-05: A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (2022) (1)
- Safety and efficacy of eribulin mesylate (EM) in patients with advanced breast cancer: The Royal Marsden experience. (2014) (1)
- Abstract LB-069: ESR1 mutations in circulating tumour DNA predict outcome to endocrine treatment in patients with estrogen receptor positive advanced breast cancer; analysis of 521 patients in the SoFEA and PALOMA3 trials (2016) (1)
- Abstract 2743: Comparison of enhanced Tagged-Amplicon Sequencing and digital PCR for circulating tumor DNA analysis in advanced breast cancer (2017) (1)
- Abstract OT2-24-02: ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy (2022) (1)
- 241PDBEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population (2017) (1)
- Directing Therapy with Circulating Tumor DNA Analysis in Advanced Breast Cancer: The PlasmaMATCH Trial (2020) (1)
- Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer (2022) (1)
- Predictors of efficacy in patients (pts) with hormone receptor–positive/ human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Subgroup analyses of PALOMA-3 (2020) (1)
- Abstract P6-18-03: Biomarker analysis of CDK 4/6 and endocrine pathways in hormone-receptor positive (HR+) advanced breast cancer (ABC) bone only disease patients: A joint analysis of PALOMA-2 and PALOMA-3 studies (2019) (1)
- Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition (2014) (1)
- Predictive Biomarkers and Personalized Medicine A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer (2010) (1)
- Targeting triple-negative sporadic and hereditary BRCA-related metastatic breast cancer (2011) (1)
- Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease. (2021) (1)
- Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA (ctDNA) in metastatic breast cancer. (2017) (1)
- Advances in the treatment of oestrogen receptor positive advanced breast cancer (2017) (1)
- Abstract P1-19-07: Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with aHER2mutation identified via ctDNA screening (CRUK/15/010) (2020) (1)
- PD05-06: Determination of HER2 Status with Analysis of Plasma DNA by Digital PCR in Patients with Metastatic Breast Cancer. (2011) (1)
- Abstract P1-19-16: Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2–negative advanced breast cancer: An updated analysis (2020) (1)
- Abstract OT3-05-02: BYLieve: A phase 2 study of alpelisib with fulvestrant or letrozole for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase (CDK)4/6 inhibi (2018) (1)
- Abstract PS5-02: Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial (2021) (1)
- Simultaneous EGFR mutation detection and copy number assessment in circulating tumour DNA (ctDNA) to inform molecular methods of therapy resistance and plasma ctDNA content in lung adenocarcinoma. (2016) (1)
- Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases (2021) (1)
- ESR1 mutations in metastatic lobular breast cancer patients (2019) (1)
- P124. Avoiding surgery in breast cancer patients with exceptional Response to neo-adjuvant chemotherapy - ASTARTE Trial (2019) (1)
- Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC) (2022) (1)
- Predicting Response to Radical Chemoradiotherapy with Circulating HPV DNA (cHPV-DNA) in Locally Advanced Uterine Cervix Cancer (2023) (1)
- Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3. (2018) (1)
- Abstract 3596: Biomarkers of response to CDK4/6 inhibitor (CDK4/6i) in hormone receptor (HR) positive and HER2-positive breast cancer (BC) patient-derived xenografts (PDX) (2018) (1)
- Abstract OT2-07-01: A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (FGFR) amplifications (FOENIX-MBC2) (2020) (1)
- 3 EGFR mutant circulating tumour DNA detection in advanced lung adenocarcinoma: optimising the application of a ctDNA diagnostic to real world clinical practice (2016) (1)
- Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib (2022) (1)
- Abstract PS5-06: Prospective testing forPIK3CA/AKT1/PTENalterations in tumor tissue from 1440 patients with advanced hormone receptor-positive HER2-negative breast cancer (HR+/HER2- BC) or triple-negative breast cancer (TNBC) screened for the IPATunity130 randomized phase 3 trial (2021) (1)
- 99P Analysis of ctDNA in advanced breast cancer reveals polyclonal disease associated with adverse outcome (2021) (1)
- Abstract P1-19-29: An integrated safety analysis of talazoparib monotherapy from five clinical trials (phase 1-3) in advanced cancers (2020) (0)
- Advances in endocrine therapy and its implications for translational research (2009) (0)
- Development of New Targeted Agents for TNBC (2012) (0)
- Medical management of breast cancer (2014) (0)
- Exceptional Response to AKT inhibition in breast cancer patients with germline PTEN mutations (2019) (0)
- Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib (2022) (0)
- Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA (2021) (0)
- Abstract P4-02-01: High-depth sequencing of circulating tumor DNA to interrogate the genetics of residual micro-metastatic disease prior to relapse in early breast cancer (2015) (0)
- Abstract PD17-06: Immunohistochemical markers and determinants of clinical response in the Penelope-B trial (2023) (0)
- Adding Palbociclib Delays Progression in HR-Positive Breast Cancer (2015) (0)
- Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis (BCLM) reveals acquisition of a lobular-like phenotype (2023) (0)
- How to integrate new drugs in the current therapeutic landscape of metastatic triple negative breast cancer (2012) (0)
- Abstract OT1-03-17: ABRAZO: An international phase 2 (2-stage, 2-cohort) study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (2016) (0)
- Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: a single-centre experience (2017) (0)
- Abstract P5-04-01: Cell cycle dynamics at single cell level dictates response to CDK4/6 inhibition (2017) (0)
- Abstract P5-05-01: Personalized Cancer Monitoring (PCM): a novel ctDNA tool to detect molecular residual disease in patients with early-stage breast cancer (2023) (0)
- Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer (2012) (0)
- Abstract P4-01-01: Molecular residual disease detection with circulating tumor DNA analysis predicts relapse in patients with early stage breast cancer (2019) (0)
- Abstract P3-07-28: SERENA-1: Updated analyses from a Phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer (2023) (0)
- P5-06-02: Response and Acquired Resistance of BRCA1-Deficient Triple-Negative Breast Cancer Xenografts to Alkylators or PARP Inhibitors. (2011) (0)
- Abstract 3608: Molecular fingerprint sequencing for minimal residual disease detection in breast cancer (2018) (0)
- Abstract P2-02-01: Withdrawn (2018) (0)
- Chemotherapy in metaplastic breast cancer; a single centre experience (2018) (0)
- Abstract P5-13-36: Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study (2022) (0)
- 336P PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC) (2020) (0)
- Circualting Tumour DNA Analysis in Breast Cancer (2017) (0)
- 21IN IS THERE A ROLE FOR NEW CYTOTOXIC AGENTS IN TNBC (2012) (0)
- Abstract PD10-08: PD10-08 Immune cell infiltration associated with poor anti-proliferative response to aromatase inhibitors in postmenopausal women with primary ER-positive HER2-negative breast cancer (2023) (0)
- Abstract P1-18-35: Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level FGFR1 amplification: Preliminary data from a phase 2 study (2022) (0)
- Abstract PD13-03: Genomic profiling of breast cancer leptomeningeal metastasis (BCLM) reveals a divergent evolution and therapeutic targets (2021) (0)
- Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance (2017) (0)
- Abstract P4-09-12: Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From BYLieve Study Cohorts A and B (2023) (0)
- Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010). (2022) (0)
- CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer (2023) (0)
- Abstract P2-08-01: Analysis of PIK3CA mutation abundance in primary breast cancer with droplet digital PCR identifies frequent sub-clonal PIK3CA mutations in ER negative and / or HER2 positive breast cancer (2013) (0)
- Experience of implementing a novel random sampling BICR audit for investigator (INV)-assessed progression-free survival (PFS) in the PALOMA-3 trial. (2017) (0)
- Metaplastic Breast Cancer (MBC): A Single Centre Experience (2018) (0)
- Abstract A184: Integrative molecular and functional profiling of HER2 amplified breast cancers to identify new gene targets. (2011) (0)
- Abstract PD10-07: PD10-07 Low plasma estradiol, low expression of estrogen responsive genes and TP53 mutations are associated with poor anti-proliferative response to aromatase inhibitors (2023) (0)
- Acquired genetic events and NF1 mutations in advanced breast cancer (2019) (0)
- Reply to J.A. Sparano et al. (2019) (0)
- Abstract PR02: Genomic rearrangements and promoter demethylation drive therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer (2013) (0)
- Clinical Benefit from Vinorelbine after Prior Treatment with Eribulin: a Single-centre Experience (2017) (0)
- Abstract 2408: A novel multiplex droplet digital PCR approach to KRAS mutation detection in circulating tumor DNA (2015) (0)
- Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX) (2016) (0)
- Abstract OT1-01-01: A randomised phase II trial of palbociclib and fulvestrant vs standard endocrine therapy in patients with ER positive HER2 negative breast cancer and ctDNA detected molecular relapse during adjuvant endocrine therapy (TRAK-ER) (2023) (0)
- Efficacyand Safety of Palbociclib (PAL) PUS Fulvestrant (F) by Geographic Region in Women with Endocrine-Resistant Hormone Receptor-Positive (HR+), Human Epiderman Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC) from Paloma-3 (2017) (0)
- Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer (2020) (0)
- Abstract C37: Molecular determinants of sensitivity and resistance to FGFR inhibition in FGFR2-amplified gastric cancer (2015) (0)
- Radiotherapy increases intestinal adverse effects and decreases social functioning compared with deferred therapy in people with localised prostate cancer (2002) (0)
- Abstract P2-01-10: Detection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgery (2022) (0)
- Abstract P1-02-01: Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer – Longer follow-up of a proof-of-principle study (2017) (0)
- Abstract P5-02-01: FGFR Signalling Drives the Growth of Triple Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo (2010) (0)
- Predicting response to radical (chemo)radiotherapy (R-CRT) with circulating HPV DNA and tumor DNA (ctDNA) analysis in locally-advanced head and neck squamous cell carcinoma (LAHNC). (2017) (0)
- Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (2022) (0)
- Abstract P1-19-14: Results from plasmaMATCH trial treatment cohort D: A phase II trial of capivasertib in patients with an AKT activation basket mutation identified via ctDNA testing or tumour sequencing (CRUK/15/010) (2020) (0)
- Genotypes , Phenotypes and Cancer Evolution (2019) (0)
- 108 Parallel siRNA and Compound Screens to Identify Molecular Determinants of Sensitivity to WEE1 Inhibition in Breast Cancer (2012) (0)
- Abstract PD17-05: Development and Validation of a Composite Biomarker Predictive of Palbociclib + Endocrine Treatment Benefit in Early Breast Cancer: PENELOPE-B and PALLAS Trials (2023) (0)
- Results from plasmaMATCH: a multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (2020) (0)
- Abstract P3-07-13: The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α (2023) (0)
- Abstract PD5-03: PD5-03 Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial (2023) (0)
- 57PRELATIONSHIP OF PIK3CA MUTATION AND PI3K PATHWAY ACTIVITY WITH ANTIPROLIFERATIVE RESPONSE TO ANASTROZOLE IN ER+ BREAST CANCER (2013) (0)
- Abstract P2-03-08: Deconstructing the molecular characteristics of ER+ HER2+ early breast cancer in the POETIC trial using multiplex immunofluorescence and gene expression profiles (2023) (0)
- Utility of early circulating tumour DNA dynamics as a surrogate for progression free survival in the BEECH phase I/II trial in metastatic breast cancer. (2019) (0)
- Abstract 2825: Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX) (2016) (0)
- Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. (2023) (0)
- Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC). (2022) (0)
- Abstract PR3: Patient derived BRCA1-deficient triple-negative breast cancer xenografts develop resistance to DNA damaging agents via genetic and epigenetic mechanisms (2012) (0)
- Abstract PD2-02: Longitudinal ctDNA sequencing using an expanded genomic panel in the PALOMA3 trial of palbociclib plus fulvestrant (2019) (0)
- Abstract P2-03-07: Multi-parametric algorithm integrating on-treatment Ki67 value and standard clinicopathological variables to predict risk of recurrences for women > 70 years old with early ER+HER2- tumours in POETIC trial (2023) (0)
- Abstract P5-19-05: Health-related quality of life during a phase 2 study of talazoparib in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO) (2018) (0)
- CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study. (2021) (0)
- Abstract HER2-06: HER2-06 Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping (2023) (0)
- Abstract P2-02-17: Circulating tumor DNA analysis with ultra-high sensitivity sequencing in metastatic breast cancer (2018) (0)
- Abstract P1-19-11: Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with anAKT1mutation identified via ctDNA screening (CRUK/15/010) (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Nicholas C. Turner?
Nicholas C. Turner is affiliated with the following schools:
